Douglas Carr - 03 Nov 2026 Form 4 Insider Report for Century Therapeutics, Inc. (IPSC)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
05 Nov 2026, 16:10:12 UTC
Prior SEC filing
15 Sep 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Douglas Carr
Filing notes and source

Key filing fact

Douglas Carr filed Form 4 for Century Therapeutics, Inc. (IPSC) on 05 Nov 2026.

Key facts

  • This page summarizes Douglas Carr's Form 4 filing for Century Therapeutics, Inc. (IPSC).
  • 1 reported transaction and 0 derivative rows are listed below.
  • Accepted by SEC: 05 Nov 2026, 16:10.

Change

  • Previous filing in this sequence was filed on 15 Sep 2026.
  • Current net transaction value: -$404.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001867173 Primary reporting owner

Carr Douglas

Relationship
SVP Finance & Operations
Address
C/O CENTURY THERAPEUTICS, INC., 25 N 38TH STREET, 12TH FLOOR, PHILADELPHIA
Signature
/s/ Douglas Carr
Signature date
05 Nov 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IPSC transaction

Common Stock

Sale

Transaction value
-$404
Shares
-266
Change %
-0.05%
Price
$1.52
Shares after
502,641
Date
03 Nov 2026
Ownership
Direct
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .